

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (original) A compound of formula (I),
(R²R³)-A⁷-A⁸-A⁹-A¹⁰-A¹¹-A¹²-A¹³-A¹⁴-A¹⁵-A¹⁶-A¹⁷-A¹⁸-A¹⁹-A²⁰-A²¹-A²²-A²³-A²⁴-A²⁵-A²⁶-A²⁷-
A²⁸-A²⁹-A³⁰-A³¹-A³²-A³³-A³⁴-A³⁵-A³⁶-A³⁷-A³⁸-A³⁹-R¹ (SEQ ID NO:412),
(I)

wherein

A⁷ is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;

A⁸ is Ala, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;

A⁹ is Glu, N-Me-Glu, N-Me-Asp or Asp;

A¹⁰ is Gly, Acc, β-Ala or Aib;

A¹¹ is Thr or Ser;

A¹² is Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, β-Nal, Cha, Trp or X¹-Phe;

A¹³ is Thr or Ser;

A¹⁴ is Ser or Aib;

A¹⁵ is Asp or Glu;

A¹⁶ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;

A¹⁷ is Ser or Thr;

A¹⁸ is Ser or Thr;

A¹⁹ is Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal or X¹-Phe;

A²⁰ is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X¹-Phe;

A²¹ is Glu or Asp;

A²² is Gly, Acc, β-Ala, Glu or Aib;

A²³ is Gln, Asp, Asn or Glu;

A²⁴ is Ala, Aib, Val, Abu, Tle or Acc;

A²⁵ is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O) or NH-CH((CH₂)_e-X³)-C(O);

A²⁶ is Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O) or NH-CH((CH₂)_e-X³)-C(O);

A²⁷ is Glu Asp, Leu, Aib or Lys;

A²⁸ is Phe, Pal, β-Nal, X¹-Phe, Aic, Acc, Aib, Cha or Trp;

A²⁹ is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;

A³⁰ is Ala, Aib or Acc;

A³¹ is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha;

A³² is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X¹-Phe or Ala;

A³³ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X¹-Phe;

A³⁴ is Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O) or NH-CH((CH₂)_e-X³)-C(O);

A³⁵ is Gly, β-Ala, D-Ala, Gaba, Ava, NH-(CH₂)_m-C(O), Aib, Acc or a D-amino acid;

A³⁶ is L-or D-Arg, D-or L-Lys, D-or L-hArg, D-or L-Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), NH-CH((CH₂)_e-X³)-C(O) or deleted;


A³⁷ is Gly, β-Ala, Gaba, Ava, Aib, Acc, Ado, Arg, Asp, Aun, Aec, NH-(CH₂)_m-C(O), HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), a D-amino acid, or deleted;

A³⁸ is D-or L-Lys, D-or L-Arg, D-or L-hArg, D-or L-Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), NH-CH((CH₂)_e-X³)-C(O), Ava, Ado, Aec or deleted;


A³⁹ is D-or L-Lys, D-or L-Arg, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), Ava, Ado, or Aec;

X¹ for each occurrence is independently selected from the group consisting of (C₁-C₆)alkyl, OH and halo;

R¹ is OH, NH₂, (C₁-C₃₀) alkoxy, or NH-X²-CH₂-Z⁰, wherein X² is a (C₁-C₁₂) hydrocarbon moiety, and Z⁰ is H, OH, CO₂H or CONH₂;




X³ is



or $-C(O)-NHR^{12}$, wherein X^4 is, independently for each occurrence, $-C(O)-$, $-NH-C(O)-$ or $-CH_2-$, and wherein f is, independently for each occurrence, an integer from 1 to 29 inclusive; each of R^2 and R^3 is independently selected from the group consisting of H, (C_1-C_{30}) alkyl, (C_2-C_{30}) alkenyl, phenyl (C_1-C_{30}) alkyl, naphthyl (C_1-C_{30}) alkyl, hydroxy (C_1-C_{30}) alkyl, hydroxy (C_2-C_{30}) alkenyl, hydroxyphenyl (C_1-C_{30}) alkyl, and hydroxynaphthyl (C_1-C_{30}) alkyl; or one of R^2 and

R^3 is $(CH_3)_2-N-\overset{\uparrow}{C}=N(CH_3)_2$, (C_1-C_{30}) acyl, (C_1-C_{30}) alkylsulfonyl, $C(O)X^5$,




; wherein Y is H, OH or NH_2 ; r is 0 to 4; q is 0 to 4; and X^5 is (C_1-C_{30}) alkyl, (C_2-C_{30}) alkenyl, phenyl (C_1-C_{30}) alkyl, naphthyl (C_1-C_{30}) alkyl, hydroxy (C_1-C_{30}) alkyl, hydroxy (C_2-C_{30}) alkenyl, hydroxyphenyl (C_1-C_{30}) alkyl or hydroxynaphthyl (C_1-C_{30}) alkyl;

e is, independently for each occurrence, an integer from 1 to 4 inclusive;

m is, independently for each occurrence, an integer from 5 to 24 inclusive;

n is, independently for each occurrence, an integer from 1 to 5, inclusive;

each of R^{10} and R^{11} is, independently for each occurrence, H, (C_1-C_{30}) alkyl, (C_1-C_{30}) acyl, (C_1-C_{30}) alkylsulfonyl, $-C((NH)(NH_2))$ or




R^{12} and R^{13} each is, independently for each occurrence, (C_1-C_{30}) alkyl;

provided that:

when A^7 is Ura, Paa or Pta, then R^2 and R^3 are deleted;

when R^{10} is (C_1-C_{30}) acyl, (C_1-C_{30}) alkylsulfonyl, $-C((NH)(NH_2))$ or



- (i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-36, -37 or -38) NH_2 or hGLP-1(7-36, -37 or -38) OH ;
- (ii) a compound of formula (I) is not an analogue of hGLP-1(7-36, -37 or -38) NH_2 or hGLP-1(7-36, -37 or -38) OH wherein a single position has been substituted by Ala;
- (iii) a compound of formula (I) is not $(\text{Arg}^{26,34}, \text{Lys}^{38})\text{hGLP-1(7-38)-E}$, $(\text{Lys}^{26}(\text{N}_\epsilon\text{-alkanoyl}))\text{hGLP-1(7-36, -37 or -38)-E}$, $(\text{Lys}^{34}(\text{N}_\epsilon\text{-alkanoyl}))\text{hGLP-1(7-36, -37 or -38)-E}$, $(\text{Lys}^{26,34}\text{-bis}(\text{N}_\epsilon\text{-alkanoyl}))\text{hGLP-1(7-36, -37 or -38)-E}$, $(\text{Arg}^{26}, \text{Lys}^{34}(\text{N}_\epsilon\text{-alkanoyl}))\text{hGLP-1(8-36, -37 or -38)-E}$, $(\text{Arg}^{26,34}, \text{Lys}^{36}(\text{N}_\epsilon\text{-alkanoyl}))\text{hGLP-1(7-36, -37 or -38)-E}$ or $(\text{Arg}^{26,34}, \text{Lys}^{38}(\text{N}_\epsilon\text{-alkanoyl}))\text{hGLP-1(7-38)-E}$, wherein E is $-\text{OH}$ or $-\text{NH}_2$;
- (iv) a compound of formula (I) is not $\text{Z}^1\text{-hGLP-1(7-36, -37 or -38)-OH}$, $\text{Z}^1\text{-hGLP-1(7-36, -37 or -38)-NH}_2$, wherein Z^1 is selected from the group consisting of:
- (a) (Arg^{26}) , (Arg^{34}) , $(\text{Arg}^{26,34})$, (Lys^{36}) , $(\text{Arg}^{26}, \text{Lys}^{36})$, $(\text{Arg}^{34}, \text{Lys}^{36})$, (D-Lys^{36}) , (Arg^{36}) , (D-Arg^{36}) , $(\text{Arg}^{26,34}, \text{Lys}^{36})$ or $(\text{Arg}^{26,36}, \text{Lys}^{34})$;
- (b) (Asp^{21}) ;
- (c) at least one of (Aib^8) , (D-Ala^8) and (Asp^9) ; and
- (d) (Tyr^7) , (N-acyl-His^7) , (N-alkyl-His^7) , (N-acyl-D-His^7) or (N-alkyl-D-His^7) ;
- (v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d); and
- (vi) a compound of formula (I) is not $(\text{N-Me-Ala}^8)\text{hGLP-1(8-36 or -37)}$, $(\text{Glu}^{15})\text{hGLP-1(7-36 or -37)}$, $(\text{Asp}^{21})\text{hGLP-1(7-36 or -37)}$ or $(\text{Phe}^{31})\text{hGLP-1(7-36 or -37)}$ or a pharmaceutically acceptable salt thereof.


2. (original) A compound according to claim 1, wherein A^{11} is Thr; A^{13} is Thr; A^{15} is Asp; A^{17} is Ser; A^{18} is Ser; A^{21} is Glu; A^{23} is Gln or Glu; A^{27} is Glu; A^{31} is Trp; or a pharmaceutically acceptable salt thereof.

3. (original) A compound according to claim 2, wherein A⁹ is Glu, N-Me-Glu or N-Me-Asp; A¹² is Phe, Acc or Aic; A¹⁶ is Val, Acc or Aib; A¹⁹ is Tyr; A²⁰ is Leu, Acc or Cha; A²⁴ is Ala, Aib or Acc; A²⁵ is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O) or HN-CH((CH₂)_e-X³)-C(O); A²⁸ is Phe; A²⁹ is Ile or Acc; A³⁰ is Ala or Aib; A³² is Leu, Acc or Cha; and A³³ is Val or Acc; or a pharmaceutically acceptable salt thereof.


4. (original) A compound according to claim 3, wherein A⁸ is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A¹⁰ is Gly; A¹² is Phe, A6c or A5c; A¹⁶ is Val, A6c or A5c; A²⁰ is Leu, A6c, A5c or Cha; A²² is Gly, β-Ala or Aib; A²⁴ is Ala or Aib; A²⁹ is Ile, A6c or A5c; A³² is Leu, A6c, A5c or Cha; A³³ is Val, A6c or A5c; A³⁵ is Aib, β-Ala, Ado, A6c, A5c or Gly; and A³⁷ is Gly, Aib, β-Ala, Ado, D-Ala or deleted; or a pharmaceutically acceptable salt thereof.

5. (original) A compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein X⁴ for each occurrence is -C(O)-; e for each occurrence is independently 1 or 2; and R¹ is OH or NH₂.


6. (original) A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R² is H and R³ is (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl,




or



7. (original) A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R¹⁰ is (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl or



8. (original) A compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein R¹⁰ is (C₄-C₂₀)acyl, (C₄-C₂₀)alkylsulfonyl or



9. (original) A compound according to claim 1 wherein said compound is
(N^α-HEPES-His)⁷, Aib^{8,35})hGLP-1(7-36)NH₂ (SEQ ID NO:3),
(N^α-HEPA-His)⁷, Aib^{8,35})hGLP-1(7-36)NH₂ (SEQ ID NO:4),
(Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:5),
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:6),
(Aib^{8,35}, Arg²⁶, Lys³⁴(N_ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:7),
(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N_ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:8),
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:9),
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-dodecanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:10),
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:11),
(Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-(4-tetradecyl-piperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:12),
(Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-tetradecylamino))hGLP-1(7-36)NH₂ (SEQ ID NO:13),
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-tetradecanoyl), β-Ala³⁷)hGLP-1(7-37)-OH (SEQ ID NO:14) or

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-tetradecanoyl))hGLP-1(7-36)-OH (SEQ ID NO:15), or a pharmaceutically acceptable salt thereof.

10. (original) A compound according to claim 9 wherein said compound is (Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:5), (Aib^{8,35}, Arg²⁶, Lys³⁴(N_ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:7), (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N_ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:8), (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:9), or (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-tetradecanoyl), β-Ala³⁷)hGLP-1(7-37)-OH (SEQ ID NO:14), or a pharmaceutically acceptable salt thereof.

11. (original) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

12. (original) A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

13. (original) A method for treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

14. (original) A method according to claim 13 wherein said disease is Type I diabetes

or Type II diabetes.

15. (original) A compound according to claim 1 wherein said compound is
(Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:71);
(β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:72);
((N^α-Me-His)⁷, Aib^{8,35})hGLP-1(7-36)NH₂ (SEQ ID NO:73);
((N^α-Me-His)⁷, Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:74);
((N^α-Me-His)⁷, Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:75);
((N^α-Me-His)⁷, Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:76);
(Aib⁸, A6c³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:77);
(Aib⁸, A5c³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:78);
(Aib⁸, D-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:79);
(Aib^{8,35}, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:16);
(Aib^{8,35}, A5c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:80);
(Aib^{8,35}, Glu²³)hGLP-1(7-36)NH₂ (SEQ ID NO:17);
(Aib^{8,24,35})hGLP-1(7-36)NH₂ (SEQ ID NO:18);
(Aib^{8,30,35})hGLP-1(7-36)NH₂ (SEQ ID NO:81);
(Aib^{8,25,35})hGLP-1(7-36)NH₂ (SEQ ID NO:82);
(Aib^{8,35}, A6c^{16,20})hGLP-1(7-36)NH₂ (SEQ ID NO:83);
(Aib^{8,35}, A6c^{16,29,32})hGLP-1(7-36)NH₂ (SEQ ID NO:84);
(Aib^{8,35}, A6c^{20,32})hGLP-1(7-36)NH₂ (SEQ ID NO:85);
(Aib^{8,35}, A6c²⁰)hGLP-1(7-36)NH₂ (SEQ ID NO:86);
(Aib^{8,35}, Lys²⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:87);
(Aib^{8,24,35}, A6c²⁰)hGLP-1(7-36)NH₂ (SEQ ID NO:88);
(Aib^{8,35}, A6c^{29,32})hGLP-1(7-36)NH₂ (SEQ ID NO:89);
(Aib^{8,24,35}, A6c^{29,32})hGLP-1(7-36)NH₂ (SEQ ID NO:90);
(Aib^{8,35}, A6c¹²)hGLP-1(7-36)NH₂ (SEQ ID NO:91);
(Aib^{8,35}, Cha²⁰)hGLP-1(7-36)NH₂ (SEQ ID NO:92);

(Aib^{8,35}, A6c³³)hGLP-1(7-36)NH₂ (SEQ ID NO:93);
(Aib^{8,35}, A6c^{20,32})hGLP-1(7-36)NH₂ (SEQ ID NO:85);
(Aib⁸, A6c^{16,20}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:94);
(Aib^{8,35}, β-Ala²²)hGLP-1(7-36)NH₂ (SEQ ID NO:95);
(Aib^{8,22,35})hGLP-1(7-36)NH₂ (SEQ ID NO:96);
(Aib^{8,35}, Glu²³, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:19);
(Aib^{8,24,35}, Glu²³, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:97);
(Aib^{8,24,25,35}, Glu²³, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:98);
(Aib^{8,24,25,35}, A6c^{16,20,32}, Glu²³)hGLP-1(7-36)NH₂ (SEQ ID NO:99);
(Aib⁸, A6c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:100);
(Aib⁸, A5c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:101);
(Aib⁸, Glu²³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:20);
(Aib^{8,24}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:102);
53: (Aib^{8,30}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:103);
(Aib^{8,25}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:104);
(Aib⁸, A6c^{16,20}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:94);
(Aib⁸, A6c^{16,29,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:105);
(Aib⁸, A6c^{20,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:106);
(Aib⁸, A6c²⁰, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:107);
(Aib⁸, Lys²⁵, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:108);
(Aib^{8,24}, A6c²⁰, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:109);
(Aib⁸, A6c^{29,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:110);
(Aib^{8,24}, A6c^{29,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:111);
(Aib⁸, A6c¹², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:112);
(Aib⁸, Cha²⁰, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:113);
(Aib⁸, A6c³³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:114);
(Aib⁸, A6c^{20,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:106);
(Aib⁸, β-Ala^{22,35})hGLP-1(7-36)NH₂ (SEQ ID NO:115);

(Aib^{8,22}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:116);
(Aib⁸, Glu²³, A6c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:117);
(Aib^{8,24}, Glu²³, A6c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:118);
(Aib^{8,24}, Glu²³, A6c³², Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:119);
(Aib^{8,24,25}, Glu²³, A6c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:120);
(Aib^{8,24,25}, A6c^{16,20,32}, Glu²³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:121);
(Aib^{8,35}, D-Arg³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:122);
(Aib^{8,35}, D-Lys³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:123);
(Aib⁸, β-Ala³⁵, D-Arg³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:124);
(Aib⁸, β-Ala³⁵, D-Lys³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:125);
(Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:21);
(Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:126);
(Aib^{8,35}, Arg^{25,26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:127);
(Aib⁸, Arg^{25,26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:128);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)OH (SEQ ID NO:129);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:130);
(Aib^{8,35,37}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:131);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl), D-Ala³⁷)hGLP-1(7-37)OH (SEQ ID NO:132);
(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:133);
(Aib^{8,35}, Arg^{26,34}, β-Ala³⁷, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:134);
(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:135);
(Aib⁸, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl), β-Ala³⁷)hGLP-1(7-37)OH (SEQ ID NO:136);
(Aib^{8,37}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:137);
(Aib^{8,35}, Arg^{26,34}, Ado³⁷)hGLP-1(7-37)OH (SEQ ID NO:138);
(Aib^{8,35}, Arg^{26,34}, Ado³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:139);
(Aib⁸, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl), D-Ala³⁷)hGLP-1(7-37)OH (SEQ ID NO 140);
(Aib^{8,37}, Arg^{26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:141);
(Aib⁸, Arg^{26,34}, β-Ala³⁷, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:142);

(Aib^{8,35}, Lys²⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:143);
(Aib^{8,35}, Lys²⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:144);
(Aib^{8,35}, Lys²⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:145);
(Aib⁸, Lys²⁶(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:146);
(Aib⁸, Lys²⁶(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:147);
(Aib⁸, Lys²⁶(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:148);
(Aib^{8,35}, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:149);
(Aib^{8,35}, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:150);
(Aib^{8,35}, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:151);
(Aib^{8,35}, Lys²⁶(N^ε-decanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:152);
(Aib^{8,35}, Lys²⁵, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:153);
(Aib^{8,35}, Lys²⁵, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:154);
(Aib^{8,35}, Lys²⁵, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:155);
(Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:156);
(Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:157);
(Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:158);
(Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:159);
(Aib⁸, Lys²⁶(N^ε-octanoyl), Arg³⁴, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:160);
(Aib⁸, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:161);
(Aib⁸, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:162);
(Aib⁸, Lys²⁶(N^ε-decanoyl), Arg³⁴, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:163);
(Aib^{8,35}, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:164);
(Aib^{8,35}, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:165);
(Aib^{8,35}, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:166);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:167);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:168);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:169);
(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:170);

(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:171);
(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:172);
(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:173);
(Aib^{8,35}, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:174);
(Aib^{8,35}, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:175);
(Aib^{8,35}, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:176);
(Aib^{8,35}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:177);
(Aib^{8,35}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:178);
(Aib^{8,35}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:179);
(Aib^{8,35}, Arg²⁶, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:180);
(Aib^{8,35}, Arg²⁶, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:181);
(Aib^{8,35}, Arg²⁶, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:182);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:183);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:184);
(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-octanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:185);
(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-decanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:186);
(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:187);
(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-hexadecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:188);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-octanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:189);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-decanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:190);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:191);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-hexadecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:192);
(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-octanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:193);
(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-decanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:194);
(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-hexadecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:195);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-octanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:189);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-decanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:190);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:191);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-hexadecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:192);
(Aib^{8,35}, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:196);
(Aib^{8,35}, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:197);
(Aib^{8,35}, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:198);
(Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:199);
(Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:200);
(Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:201);
(Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:202);
(Aib⁸, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:203);
(Aib⁸, Lys³⁴(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:204);
(Aib⁸, Lys³⁴(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:205);
(Aib⁸, A6c³², Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:206);
(Aib⁸, Glu²³, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:207);
(Aib⁸, Glu²³, A6c³², Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:208);
(Aib⁸, Arg²⁶, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:209);
(Aib⁸, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:210);
(Aib⁸, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:211);
(Aib⁸, Arg²⁶, Lys³⁴(N^ε-decanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:212);
(Aib⁸, Arg^{25,26}, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:213);
(Aib⁸, Arg^{25,26}, Lys³⁴(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:214);
(Aib⁸, Arg^{25,26}, Lys³⁴(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:215);
(Aib⁸, Arg^{25,26}, Lys³⁴(N^ε-decanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:216);
(Aib⁸, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:217);
(Aib⁸, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:218);
(Aib⁸, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:219);
(Aib⁸, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:220);
(Aib⁸, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:221);
(Aib⁸, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:222);

(Aib⁸, Arg²⁶, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:223);
(Aib⁸, Arg²⁶, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:224);
(Aib⁸, Arg²⁶, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:225);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:226);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:227);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:228);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:229);
(Aib⁸, Lys²⁵, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:230);
(Aib⁸, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:231);
(Aib⁸, Lys²⁵, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:232);
(Aib⁸, Arg^{25,26,34}, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:233);
(Aib⁸, Arg^{25,26,34}, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:234);
(Aib⁸, Arg^{25,26,34}, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:235);
(Aib⁸, Arg^{25,26,34}, β-Ala³⁵, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:236);
(Aib^{8,35}, Lys²⁶(N^ε-octanoyl), A6c³², Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:237);
(Aib^{8,35}, Lys²⁶(N^ε-tetradecanoyl), A6c³², Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:238);
(Aib^{8,35}, Lys²⁶(N^ε-hexadecanoyl), A6c³², Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:239);
(Aib^{8,35}, A6c³², Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:240);
(Aib^{8,35}, A6c³², Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:241);
(Aib^{8,35}, A6c³², Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:242);
(Aib^{8,35}, Arg²⁶, A6c³², Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:243);
(Aib^{8,35}, Arg²⁶, A6c³², Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:244);
(Aib^{8,35}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:245);
(Aib^{8,35}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:246);
(Aib^{8,35}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:247);
(Aib^{8,35}, Arg²⁶, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:248);
(Aib^{8,35}, Arg²⁶, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:249);
(Aib^{8,35}, Arg²⁶, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:250);

(Aib^{8,35}, Arg^{26,34}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:251);
(Aib^{8,35}, Arg^{26,34}, A6c³², Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:252);
(Aib^{8,35}, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:253);
(Aib^{8,35}, Arg^{26,34}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:254);
(Aib^{8,24,35}, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:255);
(Aib^{8,24,35}, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:256);
(Aib^{8,24,35}, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:257);
(Aib^{8,24,35}, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:258);
(Aib^{8,24,35}, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:259);
(Aib^{8,24,35}, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:260);
(Aib^{8,24,35}, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:261);
(Aib^{8,24,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:262);
(Aib^{8,24,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:263);
(Aib^{8,24,35}, Glu²³, A6c³², Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:264);
(Aib^{8,35}, Glu²³, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:265);
(Aib^{8,35}, Glu²³, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:266);
(Aib^{8,35}, Glu²³, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:267);
(Aib^{8,35}, Glu²³, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:268);
(Aib^{8,35}, Glu²³, A6c³², Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:269);
(Aib^{8,35}, Glu²³, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:270);
(Aib^{8,35}, Glu²³, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:271);
(Aib^{8,35}, Glu²³, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:272);
(Aib^{8,35}, Glu²³, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:273);
(Aib^{8,35}, Glu²³, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:274);
(Aib^{8,35}, Glu²³, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:275);
(Aib^{8,35}, Glu²³, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:276);
(Aib^{8,35}, Glu²³, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:277);
(Aib^{8,35}, Glu²³, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:278);

(Aib^{8,30,35}, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:279);
(Aib^{8,30,35}, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:280);
(Aib^{8,30,35}, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:281);
(Aib^{8,30,35}, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:282);
(Aib^{8,30,35}, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:283);
(Aib^{8,30,35}, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:284);
(Aib^{8,30,35}, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:285);
(Aib^{8,30,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:286);
(Aib^{8,30,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:287);
(Aib^{8,35}, Glu²³, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:288);
(Aib^{8,35}, Glu²³, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:289);
(Aib^{8,35}, Glu²³, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:290);
(Aib^{8,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:291);
(Aib^{8,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:292);
(Aib^{8,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:293);
(Aib^{8,24,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:294);
(Aib^{8,24,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:295);
(Aib^{8,24,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:296);
(Aib^{8,24,30,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:297);
(Aib^{8,24,30,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:298);
(Aib^{8,24,30,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:299);
((N^α-HEPES-His)⁷, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:300);
((N^α-HEPES-His)⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:301);
((N^α-HEPES-His)⁷, Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:302);
((N^α-HEPA-His)⁷, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:303);
((N^α-HEPA-His)⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:304);

((N^α-HEPA-His)⁷, Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:305);
((N^α-tetradecanoyl-His)⁷, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:306);
((N^α-tetradecanoyl-His)⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:307);
((N^α-tetradecanoyl-His)⁷, Aib^{8,35})hGLP-1(7-36)NH₂ (SEQ ID NO:308);
((N^α-tetradecanoyl-His)⁷, Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:309);
((N^α-tetradecanoyl-His)⁷, Arg^{26,34}, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:310);
((N^α-tetradecanoyl-His)⁷, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:311);
((N^α-tetradecanoyl-His)⁷, Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:312);
((N^α-tetradecanoyl-His)⁷, Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:313);
((N^α-tetradecanoyl-His)⁷, Arg^{25,26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:314);
((N^α-tetradecanoyl-His)⁷, Aib^{8,35}, Arg^{25,26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:315);
((N^α-tetradecanoyl-His)⁷, Aib⁸, Arg^{25,26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:316);
(Aib^{8,35}, Lys²⁶(N^ε-octanesulfonyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:317);
(Aib^{8,35}, Lys²⁶(N^ε-dodecanesulfonyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:318);
(Aib^{8,35}, Lys²⁶(N^ε-hexadecanesulfonyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:319);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-octanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:320);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-dodecanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:321);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-hexadecanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:322);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-octanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:323);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:324);
(Aib^{8,35}, Asp²⁶(1-(4-decylpiperazine)), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:325);
(Aib^{8,35}, Asp²⁶(1-(4-dodecylpiperazine)), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:326);
(Aib^{8,35}, Asp²⁶(1-(4-tetradecylpiperazine)), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:327);
(Aib^{8,35}, Asp²⁶(1-(4-hexadecylpiperazine)), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:328);
(Aib^{8,35}, Arg²⁶, Asp³⁴(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:329);
(Aib^{8,35}, Arg²⁶, Asp³⁴(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:330);
(Aib^{8,35}, Arg²⁶, Asp³⁴(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:331);
(Aib^{8,35}, Arg²⁶, Asp³⁴(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:332);

(Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:333);
(Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:334);
(Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:335);
(Aib^{8,35}, Arg^{26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:336);
(Aib^{8,35}, Arg^{26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:337);
(Aib^{8,35}, Arg^{26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:338);
(Aib^{8,35}, Arg^{26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:339);
(Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:340);
(Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:341);
(Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:342);
(Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:343);
(Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:344);
(Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:345);
(Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:346);
(Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:347);
(Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:348);
(Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:349);
(Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:350);
(Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:351);
(Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:352);
(Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:353);
(Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:354);
(Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:355);
(Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:356);
(Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:357);
(Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:358);
(Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:359);
(Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:360);

(Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:361);
(Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:362);
(Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:363);
(Aib^{8,35}, Arg^{26,34}, Glu³⁶(1-dodecylamino))hGLP-1(7-36)NH₂ (SEQ ID NO:364);
(Aib^{8,35}, Glu²⁶(1-dodecylamino), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:365);
(Aib^{8,35}, Arg²⁶, Glu³⁴(1-dodecylamino))hGLP-1(7-36)NH₂ (SEQ ID NO:366);
(Aib^{8,35,37}, Arg^{26,34}, Glu³⁸(1-dodecylamino))hGLP-1(7-38)NH₂ (SEQ ID NO:367);
(Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:368);
(Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:369);
(Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:370);
(Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:371);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:372);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:373);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:374);
(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:375);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:376);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:377);

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:378);

(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:379);

(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:380);

(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:381);

(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:382);

(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:383);

(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:384);

(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:385);

(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:386);

(Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:387);

(Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:388);

(Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:389);

(Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:390);

(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:391);

(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:392);

(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:393);

(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:394);

(Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:395);

(Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:396);

(Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:397);

(Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:398);

(Aib^{8,35}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:399);

(Aib^{8,35}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:400);

(Aib^{8,35}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:401);

(Aib^{8,35}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:402);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:403);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:404);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:405);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:406);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:407);
(Aib^{8,35}, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:408);
(Aib^{8,35}, Arg^{26,34}, Ava³⁷, Ado³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:409);
(Aib^{8,35}, Arg^{26,34}, Asp³⁷, Ava³⁸, Ado³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:27);
(Aib^{8,35}, Arg^{26,34}, Aun³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:28);
(Aib^{8,17,35})hGLP-1(7-36)NH₂ (SEQ ID NO:29);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, D-Asp³⁷, Ava³⁸, Aun³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:30);
(Gly⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:31);
(Ser⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:32);
(Aib⁸, Glu^{22,23}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:33);
(Gly⁸, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:34);
(Aib⁸, Lys¹⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:35);
(Aib⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:36);
(Aib⁸, Lys³³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:37);
(Aib⁸, Lys¹⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:38);
(Aib⁸, D-Arg³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:39);
(Aib⁸, β-Ala³⁵, D-Arg³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:40);
(Aib^{8,27}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:41);
(Aib^{8,27}, β-Ala^{35,37}, Arg³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:42);
(Aib^{8,27}, β-Ala^{35,37}, Arg^{38,39})hGLP-1(7-39)NH₂ (SEQ ID NO:43);
(Aib⁸, Lys^{18,27}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:44);
(Aib⁸, Lys²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:45);
(Aib⁸, β-Ala³⁵, Arg³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:46);
(Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:47);
(Aib⁸, D-Arg³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:48);
(Aib⁸, β-Ala³⁵, Arg³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:49);

(Aib⁸, Phe³¹, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:50);
(Aib^{8,35}, Phe³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:51);
(Aib^{8,35}, Nal³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:52);
(Aib^{8,35}, Nal^{28,31})hGLP-1(7-36)NH₂ (SEQ ID NO:53);
(Aib^{8,35}, Arg^{26,34}, Nal³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:54);
(Aib^{8,35}, Arg^{26,34}, Phe³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:55);
(Aib^{8,35}, Nal^{19,31})hGLP-1(7-36)NH₂ (SEQ ID NO:56);
(Aib^{8,35}, Nal^{12,31})hGLP-1(7-36)NH₂ (SEQ ID NO:57);
(Aib^{8,35}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:58);
(Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:59);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-dodecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:60);
(Aib⁸, β-Ala³⁵, Ser³⁷(O-decanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:61);
(Aib^{8,27}, β-Ala^{35,37}, Arg³⁸, Lys³⁹(N^ε-octanoyl))hGLP-1(7-39)NH₂ (SEQ ID NO:62);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-octanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:63);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-decanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:64);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-tetradecanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:65);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-dodecanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:410); or
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-dodecanoyl))hGLP-1(8-37)NH₂ (SEQ ID NO:411);
or a pharmaceutically acceptable salt thereof.

16. (original) A compound according to claim 15 wherein said compound is
(Aib^{8,35}, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:16);
(Aib^{8,35}, Glu²³)hGLP-1(7-36)NH₂ (SEQ ID NO:17);
(Aib^{8,24,35})hGLP-1(7-36)NH₂ (SEQ ID NO:18);
(Aib^{8,35}, Glu²³, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:19);
(Aib⁸, Glu²³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:20);
(Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:21);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:22);

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:23);
(Aib^{8,35}, Lys²⁵, Arg^{26,34}Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:24);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-Aec-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:25);
(Aib^{8,35}, Arg^{26,34}, Ava³⁷, Ado³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:26);
(Aib^{8,35}, Arg^{26,34}, Asp³⁷, Ava³⁸, Ado³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:27);
(Aib^{8,35}, Arg^{26,34}, Aun³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:28);
(Aib^{8,17,35})hGLP-1(7-36)NH₂ (SEQ ID NO:29);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, D-Asp³⁷, Ava³⁸, Aun³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:30);
(Gly⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:31);
(Ser⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:32);
(Aib⁸, Glu^{22,23}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:33);
(Gly⁸, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:34);
(Aib⁸, Lys¹⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO: 35);
(Aib⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:36);
(Aib⁸, Lys³³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:37);
(Aib⁸, Lys¹⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:38);
(Aib⁸, D-Arg³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:39);
(Aib⁸, β-Ala³⁵, D-Arg³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:40);
(Aib^{8,27}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:41);
(Aib^{8,27}, β-Ala^{35,37}, Arg³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:42);
(Aib^{8,27}, β-Ala^{35,37}, Arg^{38,39})hGLP-1(7-39)NH₂ (SEQ ID NO:43);
(Aib⁸, Lys^{18,27}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:44);
(Aib⁸, Lys²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:45);
(Aib⁸, β-Ala³⁵, Arg³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:46);
(Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:47);
(Aib⁸, D-Arg³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:48);
(Aib⁸, β-Ala³⁵, Arg³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:49);
(Aib⁸, Phe³¹, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:50);

(Aib^{8,35}, Phe³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:51);
(Aib^{8,35}, Nal³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:52);
(Aib^{8,35}, Nal^{28,31})hGLP-1(7-36)NH₂ (SEQ ID NO:53);
(Aib^{8,35}, Arg^{26,34}, Nal³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:54);
(Aib^{8,35}, Arg^{26,34}, Phe³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:55);
(Aib^{8,35}, Nal^{19,31})hGLP-1(7-36)NH₂ (SEQ ID NO:56);
(Aib^{8,35}, Nal^{12,31})hGLP-1(7-36)NH₂ (SEQ ID NO:57);
(Aib^{8,35}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:58);
(Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:59);
(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-dodecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:60);
(Aib⁸, β-Ala³⁵, Ser³⁷(O-decanoyl))hGLP-1(7-37)-NH₂ (SEQ ID NO:61);
(Aib^{8,27}, β-Ala^{35,37}, Arg³⁸, Lys³⁹(N^ε-octanoyl))hGLP-1(7-39)NH₂ (SEQ ID NO:62);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-octanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:63);
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-decanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:64); or
(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-tetradecanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:65);
or a pharmaceutically acceptable salt thereof.

17-18. (cancelled)